UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 104

Sortiert nach

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors

British journal of cancer, 2020-07, Vol.123 (2), p.176-177

2020

Volltextzugriff (PDF)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Frontiers in oncology, 2019-07, Vol.9, p.666-666

2019

Volltextzugriff (PDF)

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

Molecular oncology, 2015-04, Vol.9 (4), p.749-757

2015

Volltextzugriff (PDF)

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

Nature reviews. Clinical oncology, 2015-09, Vol.12 (9), p.541-552

2015

Volltextzugriff (PDF)

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer

International journal of molecular sciences, 2021-04, Vol.22 (9), p.4687

2021

Volltextzugriff (PDF)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer

NPJ breast cancer, 2022-02, Vol.8 (1), p.24-24, Article 24

2022

Volltextzugriff (PDF)

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology

Biomolecules (Basel, Switzerland), 2020-12, Vol.10 (12), p.1677

2020

Volltextzugriff (PDF)

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Breast cancer research : BCR, 2021-03, Vol.23 (1), p.38-38, Article 38

2021

Volltextzugriff (PDF)

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

NPJ breast cancer, 2018-11, Vol.4 (1), p.38-10, Article 38

2018

Volltextzugriff (PDF)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Breast cancer research : BCR, 2019-05, Vol.21 (1), p.71-71, Article 71

2019

Volltextzugriff (PDF)

Charting differentially methylated regions in cancer with Rocker-meth

Communications biology, 2021-11, Vol.4 (1), p.1249-1249, Article 1249

2021

Volltextzugriff (PDF)

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data

BMC genomics, 2018-12, Vol.19 (1), p.960-960, Article 960

2018

Volltextzugriff (PDF)

A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

Clinical cancer research, 2005-07, Vol.11 (13), p.4741-4748

2005

Volltextzugriff (PDF)

Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients

Translational oncology, 2023-01, Vol.27, p.101585-101585, Article 101585

2023

Volltextzugriff (PDF)

Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts

Cancer research (Chicago, Ill.), 2008-09, Vol.68 (18), p.7493-7501

2008

Volltextzugriff (PDF)

The role of abemaciclib in treatment of advanced breast cancer

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758835918776925-1758835918776925

2018

Volltextzugriff (PDF)

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758835918815591-1758835918815591

2018

Volltextzugriff (PDF)

Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib

Cells (Basel, Switzerland), 2020-03, Vol.9 (3), p.668

2020

Volltextzugriff (PDF)

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

Therapeutic advances in medical oncology, 2019, Vol.11, p.1758835919891608

2019

Volltextzugriff (PDF)

Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse

Applied sciences, 2021-12, Vol.11 (23), p.11120

2021

Volltextzugriff (PDF)

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Cancers, 2014-03, Vol.6 (2), p.684-707

2014

Volltextzugriff (PDF)

Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance

Biomarkers in medicine, 2020-05, Vol.14 (7), p.495-498

2020

Volltextzugriff (PDF)

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy

Current opinion in oncology, 2014-11, Vol.26 (6), p.568-575

2014

Volltextzugriff (PDF)

CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

Cancer treatment reviews, 2021-02, Vol.93, p.102136-102136, Article 102136

2021

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Englisch
(103)
Japanisch
(10)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(61)
Life Sciences & Biomedicine
(60)
Oncology
(48)
Humans
(37)
Breast Cancer
(35)
Female
(32)
Breast Neoplasms - Drug Therapy
(27)
Breast Neoplasms - Pathology
(16)
Breast Neoplasms - Genetics
(13)
Tumors
(13)
Cancer
(12)
Endocrine Therapy
(12)
Metastasis
(12)
Biomarkers
(11)
Breast Neoplasms - Metabolism
(11)
Patients
(11)
Receptors, Estrogen - Metabolism
(11)
Cdk4/6 Inhibitors
(10)
Receptor, Erbb-2 - Metabolism
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer

Cell-Free DNA-Methylation-Based Methods and Applications in Oncology

Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial

Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial

Charting differentially methylated regions in cancer with Rocker-meth

ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data

A Meta-Analysis on the Interaction between HER-2 Expression and Response to Endocrine Treatment in Advanced Breast Cancer

Risk assessment of disease recurrence in early breast cancer: A serum metabolomic study focused on elderly patients

Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts

The role of abemaciclib in treatment of advanced breast cancer

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib

A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse

Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer?

Thymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistance

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy

CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

Suchergebnisse filtern